Vaccinating nine in 10 girls under the age of 15 years against cervical cancer, and improved screening and treatment of women could reduce infections by 40% and save 5 million lives by 2050, the World Health Organization (WHO) said.
Routine medical tests critical for detecting and monitoring cancer and other conditions plummeted in the United States since mid-March, as the coronavirus spread and public officials urged residents to stay home, according to a new report by Komodo Health.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The U.S. Food and Drug Administration placed Princeton, N.J.-based Advaxis’ Phase III clinical trial of axalimogene filolisbac (AXAL) in advanced cervical cancer on partial clinical hold.
Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.
Regeneron Pharmaceuticals Inc. and ISA Pharmaceuticals B.V. announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with the PD-1 antibody cemiplimab (REGN2810).
Amgen, in partnership with Allergan, announced that the U.S. Food and Drug Administration approved its biosimilar for Genentech’s Avastin. The biosimilar Mvasi (bevacizumab-awwb) was approved for a broad swath of cancer indications.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.
The China Food and Drug Administration has approved GSK’s human papillomavirus vaccine Cervarix for use in the country to help women fight cervical cancer.